Clinical Trial Update: CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial comparing CB-839 with cabozantinib vs cabozantinib with placebo in metastatic renal cell carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• CB-839 (telaglenastat)
• cabozantinib (cabozantinib)

Snippet

Sponsor: Calithera Biosciences, Inc | Conditions: Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2023-03-20